OncoSwift® Bladder Multi-Omics
Unique Identifier:
ML-S001
Name on Requisition:
OncoSwift® Bladder Multi-Omics
Product Line:
ST
Panel Group:
Solid Tumor Panels
Panel Name:
OncoSwift® Bladder Multi-Omics
Methodology
Molecular
NGS
Test Description and clinical significance
Genes
ALK, AKT1, AR, ATM, BAP1, BRAF, BRCA1, BRCA2, CDKN2A, CCND1, CREBBP, EGFR, ERBB2, ERBB3, ERBB4, FANCA, FBXW7, FGFR1, FGFR2, FGFR3, HRAS, KDM6A, KMT2A, KMT2C, KMT2D, KRAS, MAP2K1, NF1, NRAS, PIK3CA, PTEN, RB1, RET, SMARCA4, STAG2, TERT, TP53.
Disease:
urothelial and bladder cancers
The OncoSwift® Bladder Multi-Omics Panel is designed to detect genomic and transcriptomic alterations relevant to urothelial and bladder cancers. This assay integrates DNA mutation profiling, RNA fusion detection, and expression analysis to identify diagnostic biomarkers, stratify prognosis, and support selection of targeted and immunotherapy options.
Specimen Requirements
Preparation:
FFPE tissue or slides
Collection:
In case of FFPE sections, 5-10 sections are recommended at 4 to 10 micron.
Stability:
Stored at room temperature
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative. Insufficient specimen (less than 10% of tumor). Bacterial over growth. Submitted with incomplete requisition form (unless a requisition is subsequently sent). Unlabeled or improperly labeled specimens, without contact information or when failing to
reach the ordering physician for clarification. Decalcified specimens. Improperly stored DNA.
Storage & Transport
Store FFPE blocks and slides at room temperature. Slides may be stored at ambient
CPT(s)
81459
New York Approved
Yes
TAT
7
Requisition Type
ST
Levels of Service
Full
DexS Code
Z05C6
Prefix
MI
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
